RxDoctor Payments Data

John Ryden, MD

Family Medicine · Virginia, MNNPI 1578589255

Payments from drug & device makers

$552in general payments, 2019–2025

Across 37 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$81
  • Boehringer Ingelheim$63
  • E.r. Squibb & Sons, L.L.C.$54
  • Travere Therapeutics, Inc.$51
  • AstraZeneca$46
  • Exact Sciences$42
  • plus $216 from 11 others

What the payments were for

  • Food & beverage$552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$552 in reported general payments places this provider in the 85th percentile of 1,162 family medicine providers in Minnesota.

See all family medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$56,297
Medicare patients
143
Services billed
2,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$124,548
OzempicSemaglutide95$102,109
XareltoRivaroxaban97$92,498
RybelsusSemaglutide25$45,834
JardianceEmpagliflozin37$37,446
TrulicityDulaglutide26$37,446
JanuviaSitagliptin Phosphate39$35,575
MounjaroTirzepatide31$32,949
Breo ElliptaFluticasone/Vilanterol37$24,985
MyrbetriqMirabegron27$19,265
OxycontinOxycodone Hcl16$13,479
Incruse ElliptaUmeclidinium Bromide22$12,997
FarxigaDapagliflozin Propanediol16$11,051
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$9,156
Xtampza ErOxycodone Myristate12$8,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$26$147,943120 claims
Boehringer IngelheimJardiance$63$37,44637 claims
Astellas Pharma US IncMyrbetriq$23$19,26527 claims
AstraZenecaFarxiga$46$11,05116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,162 family medicine providers in Minnesota.

Other family medicine in Virginia

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →